-
On August 4, 2025, the CDC confirmed the first US human case of New World screwworm in Maryland, involving a patient recently returned from El Salvador. The flesh-eating parasite, primarily affecting livestock, has been spreading northward through Central America and Mexico since 2023. The US is responding with plans for a sterile fly facility in Texas to prevent reintroduction and protect the cattle industry.
-
On October 10, 2025, President Donald Trump announced a deal with AstraZeneca to lower drug prices for Medicaid patients by matching the lowest prices in developed countries. The agreement includes AstraZeneca's commitment to invest $50 billion in U.S. manufacturing by 2030 and participation in the upcoming TrumpRx website, which will sell discounted drugs directly to consumers starting in early 2026.
-
A federal judge has temporarily halted changes to HUD's housing funding criteria, which critics say were politically motivated to exclude communities supporting sanctuary policies and transgender rights. The lawsuit argues HUD lacked proper authority and that the changes could harm vulnerable populations. The case remains ongoing as the court reviews the administration's actions.
-
North Carolina's medical debt cancellation program, launched 15 months ago, has helped nearly a quarter of residents, erasing an average of $2,600 per person. The initiative, part of broader Medicaid incentives, has surpassed initial estimates, with hospitals removing debt from credit reports and aiding millions in financial recovery.
-
As of November 2025, US schools and universities face escalating conflicts over antisemitism and diversity, equity, and inclusion (DEI) policies. California confronts a federal lawsuit challenging a new law aimed at combating antisemitism in schools. Universities like UVA and UCLA negotiate with the federal government over DEI bans and antisemitism probes, while K-12 schools report rising antisemitic harassment since 2023.
-
Liberia's government announced a significant increase in medicine procurement, with $10 million allocated for 2024-2025. The initiative aims to reduce drug shortages, improve accountability, and strengthen healthcare access nationwide, supported by government leadership and community involvement.
-
On December 1-2, 2025, WHO issued its first guidelines recommending long-term use of GLP-1 drugs like Wegovy and Mounjaro for obesity treatment, recognizing obesity as a chronic disease. The US government finalized deals lowering prices for these drugs under Medicare and Medicaid, expanding coverage to more patients. Despite benefits, studies show weight and health gains reverse if treatment stops, highlighting need for ongoing care.